Evidence
Evidence by condition
LAST REVIEWED 2026-06-30 · 815 SOURCES · 0 CORRECTIONS
Evidence-grade pages use the same skeptical template: evidence level, human studies, sample sizes, design quality, outcomes, limitations, safety signals, and what is not proven.
| Condition | Evidence | Setting | What's not proven |
|---|---|---|---|
| Opioid use disorder | Evidence: Early humanEarly human and observational | Observational detoxification reports, follow-up studies, and registered oral Ibogaine withdrawal research. | Ibogaine is not proven to cure opioid addiction. |
| Alcohol use disorder | Evidence: Very limitedVery limited human evidence | FDA allowed an early phase U.S. Noribogaine hydrochloride study to proceed after an IND submission in April 2026. | Noribogaine is not FDA-approved for alcohol use disorder. |
| Traumatic brain injury | Evidence: Limited observationalLimited observational evidence | A 30-person veteran prospective observational study and later neurophysiology work drew attention and require side-by-side design-limit explanation. | Ibogaine is not proven as a general TBI treatment. |
| PTSD and trauma symptoms | Evidence: Limited observationalLimited observational evidence | PTSD-related signals often appear within veteran or substance-use populations rather than standalone PTSD trials. | Ibogaine is not proven as a PTSD treatment. |
| Depression and mood symptoms | Evidence: Very limitedVery limited human evidence | Mood improvements appear in some Ibogaine-related observational and veteran studies, usually as secondary outcomes. | Ibogaine is not proven as a depression treatment. |
| Parkinson's disease | Evidence: Case report onlySingle case report only | A 2026 peer-reviewed case report describes one patient treated with low-dose Ibogaine hydrochloride over 80 days using validated Parkinson's instruments. | Ibogaine is not proven as a Parkinson's treatment. |
| Withdrawal | Evidence: Limited observationalLimited observational evidence | Withdrawal and craving findings appear in OUD studies, observational detoxification reports, and substance-use reviews. | Craving reduction or withdrawal relief is not the same as a cure. |
| Cravings | Evidence: Limited observationalLimited observational evidence | Withdrawal and craving findings appear in OUD studies, observational detoxification reports, and substance-use reviews. | Craving reduction or withdrawal relief is not the same as a cure. |
Synthesis shelf: reviews and meta-analysis
Single studies and news items are easy to over-read. A synthesis shelf points to work that summarizes across studies: narrative reviews, a scoping review of cardiac safety, and attempts at systematic review or meta-analysis of ibogaine for substance use. A review that pools weak underlying studies is still limited by those studies; synthesis does not upgrade the strength of the evidence, it describes it. Reviewers repeatedly note the absence of an efficacy randomized controlled trial of ibogaine.
Historical framing note: reviews spanning roughly thirty years of ibogaine research consistently describe promising observational signals alongside serious safety concerns and an evidence base that has not reached confirmatory trials.